Metformin in prevention and treatment of antipsychotic-induced weight gain: A systematic review and meta-analysis
Clinical efficacy: evidence from the OASIS program Phase 3 OASIS trials demonstrated clinically meaningful weight reductions with oral semaglutide: OASIS 1: up to 15.1% body weight reduction with 50 mg vs 2.4% with placebo OASIS 2: 14.3% reduction in an East Asian population OASIS 4: 13.6% reduction with the 25 mg dose vs 2.2% with placebo These results confirm that oral semaglutide can achieve weight loss outcomes comparable to injectable GLP-1 RA formulations
This is one of its primary advantages over full growth hormone therapy and makes it safe to combine with Retatrutide, which does influence insulin signaling through its GIP receptor activity
Imaging studies offer the most objective assessment but add cost and complexity
Many people experience temporary gastrointestinal symptomssuch as nausea, diarrhea, or constipationespecially during the dose-increase phase
Lindsey Smith explains in the article that a responsible provider must evaluate each patient's medical history, medications, and goals before recommending any combined plan
